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High prevalence of marijuana smokers in acute coronary syndromes
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Background: Despite marijuana is the most frequent drug use worldwide,
there is no prospective clinical data of its implication in acute coronary syn-
dromes (ACS). The aim of this study was to evaluate the prevalence of mari-
juana smokers in young people admitted to intensive unit care for ACS.
Material and Methods: From September 2010 to Mars 2011, we prospec-
tively included all patients below 50 years old admitted for ACS at the University
Hospital of Toulouse, France and assessed their use of Marijuana by medical ques-
tioning and systematic urinary assay. Patients were divided into 2 groups (mari-
juana smokers and no marijuana smokers) according to the presence of marijuana
in urines. Parametric and non-parametric tests were used for groups comparison.
Results: 63 patients were included. Mean age was 42±7 years old and 52
(82.5%) patients were male. In this cohort, 23.8% (15) were recognized as
marijuana smokers (MS). There was no difference in classical cardiovascular
risk factors, age and gender between the two groups. Interestingly, MS present
significative more non ST elevation myocardial infarction than non MS
patients (67% vs 29.2%; p=0.009). There was no difference in the coronary
status but a high frequency of multivessel coronary disease (respectively
46.6% and 45.8%, p=0.95) in the two groups. There was no death in MS
group whereas two in the non MS group. No difference was observed in left
ejection fraction at hospital discharge (55% vs 52%, p=0.291). Marijuana
addiction is characterized by an 86.7% use in the 24 hours preceding the ACS
and 73.3% in the last three hours. 
Conclusion: Marijuana use is frequent, especially in the few hours preceding the
event, and probably underdiagnosed in ACS of people below 50 years old. Clinical
presentation of ACS is different in this group with less ST elevation suggesting a
more complex coronary artery disease. Multicentric study should be achieved to
assess epidemiology and pathophysiolgical role of marijuana use in ACS. 
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Objectives: To perform a comprehensive analysis of all determinants of
definite early stent thrombosis (ST) to identify the risk and the modifiable fac-
tors of early ST.
Methods: Using a web-based case collection and reporting system,
123 patients with definite EST on dual antiplatelet therapy were matched 2:1
according to age and gender with 246 controls. All patients were genotyped
for 23 genetic variants involved in clopidogrel metabolism (CYP2C19,
CYP2C9, CYP2B6, CYP3A5, POR, ABCB1, PON1), platelet receptor func-
tion (P2Y12, ITGB3), and the coagulation and fibrinolytic system (MTHFR,
Factor V, Fibrinogen, Prothrombin, PAI1 and VKORC1).
Results: CYP2C19*2 (ORund=2.53, 95% CI [1.61-3.97], p<0.0001) and
ABCB1 TT3435 (ORund=2.01, 95% CI [1.22-3.30], p=0.006) carriers were
more frequent among patients with EST than controls while CYP2C19*17
(ORund=0.53, 95% CI [0.31-0.88], p=0.01) and ITGB3 PlA2 (ORund=0.50,
95% CI [0.29-0.87], p=0.01) carriers were less frequent. The accuracy of the
clinical model to discriminate between EST and controls (AUC 0.72, 95% CI
[0.66-0.77] did not differ significantly from the genetic model (AUC 0.68,
95% CI [0.62-0.73] (p=0.34), although combining both led to a significant
improvement in the discriminatory power of the model (AUC 0.78, 95% CI
[0.73-0.83], p=0.004). Among all independent predictors of early ST, the use
of high clopidogrel loading doses (OR=0.73, 95% CI[0.57-0.94], p=0.01) and
proton pump inhibitors (OR=2.19, 95% CI [1.28-3.72], p=0.004) were the
only modifiable factors.
Conclusion: In addition to established clinical and angiographic factors,
three genes involved in clopidogrel metabolism and platelet receptor function
(CYP2C19, ABCB1, ITGB3) were significantly significantly improved the
ability to predict early ST. PPI use and clopidogrel dose were both indepen-
dently correlated with the risk of early ST, suggesting that the final amount of
active metabolite generated is a major factor of prevention.
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Background: The impact of the timing of presentation of patients with
acute myocardial infarction (AMI) and the subsequent effect on management
and prognosis have not been fully investigated. 
Methods and results: A total of 1315 patients admitted for AMI between
January 1995 and December 2010 were included in our MonastIR AMI
(MIRAMI) registry. We deliberately excluded from the analysis patients who pre-
sented late and therefore did not receive a reperfusion strategy. A total of 768
patients did receive one of the two reperfusion strategies (thrombolysis or primary
angioplasty) and therefore were included in this analysis. There were no signifi-
cant differences on the frequency of AMI between the different periods of the day
and particularly between working and off-work hours. (p=0.92). Primary angio-
plasty was more frequently performed between 8 and 12 a.m (p=0.03). Thrombol-
ysis was more given between 8 and 12 p.m (p=0.03). AMI was more frequent
during winter (31.7% with p= 0.007) but mortality was higher during autumn
(p=0.008). There were no differences in mortality and heart failure according to
the hour of presentation (p=0.77 and p=0.44 respectively). 
Conclusion: The time of presentation of patients with AMI did have an
impact on the selection of the reperfusion strategy but not on the in-hospital
outcome. There is clearly an impact of the season with a higher in-hospital
mortality during autumn.
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Background: Carriers of the loss-of-function CYP2C19*2 genetic variant
have lower active metabolite levels and diminished platelet inhibition after
clopidogrel loading.
Objectives: To determine the pharmacokinetic (PK) and pharmacody-
namic (PD) responses to two LDs (LD) of clopidogrel according to carriage
of CYP2C19*2 genetic variant. 
Methods: Young post-MI patients heterozygous (wt/*2, n=43) or homo-
zygous (*2/*2, n=8) for the CYP2C19*2 genetic variant were matched with
patients not carrying the variant (wt/wt, n=58). All patients were randomized
to 300mg or 900mg clopidogrel LD. The relative reduction in residual platelet
aggregation (RR-RPA in %) and the area under the plasma concentration
(AUC0-6) – time curve of active metabolite) from baseline to six-hours post
loading were compared according to both LD and CYP2C19*2 carriage.
Results: The 300 mg LD led to a gene-dose effect for RR-RPA (–65.7±35.9%
in wt/wt vs. –48.0±38.4% in wt/*2 vs.-14.6±32.4% in *2/*2; overall p-
value=0.003, p=0.03 for wt/wt versus wt/*2, p=0.04 for wt/*2 versus *2/*2)
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with minor effect in *2/*2 carriers. After 900mg LD, the effect of the
CYP2C19*2 variant on platelet inhibition was fully compensated in wt/*2 car-
riers but not in *2/*2 carriers (–83.6±25.8% in wt/wt vs. –77.2±26.9% in wt/
*2 vs. –29.5±26.8% in *2/*2; overall p-value=0.0003, p=0.20 for wt/wt versus
wt/*2, p<0.001 for wt/*2 versus *2/*2). A similar pattern was observed for the
active metabolite AUC0-6 and there was a significant correlation between PK
and PD responses irrespective of the LD. 
Conclusion: Carriers of CYP2C19*2 display significant lower responses to
clopidogrel with a gene dose-effect. Clopidogrel resistance can be overcome by
increasing the dose in heterozygous carriers but not in homozygous carriers. 
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Purpose: There is no consensus on how to manage the switch from clopido-
grel to prasugrel immediately after a clopidogrel loading dose (LD). The aim of
this study was to evaluate the pharmacodynamic response of switching patients in
this situation and comparing two prasugrel reloading doses (RD) by using three
laboratory tests. Methods: Patients hospitalized for acute coronary syndrome
(ACS) who received a 300 mg LD of clopidogrel before admission were referred
for inclusion. Their platelet response to the P2Y12 inhibitor was tested with vaso-
dilator-stimulated phosphoprotein phosphorylation (VASP), Verify Now assay
and light transmission aggregometry (LTA) on admission (T1). Then, patients
were immediately randomized for 2 RD of prasugrel (10 mg or 30 mg) and
platelet response was tested again by the same methods (T2). Results: 20 patients
were included in each group. All T1 and T2 analyses were performed during the
first 24 hours after hospitalization. Compared with a 300 mg LD of clopidogrel,
the proportion of patients with platelet hyporesponsiveness for VASP to the
P2Y12 inhibitor was lower after the prasugrel RD: 8 vs 1 (p<0.001) in the 10 mg
prasugrel group and 12 vs none (p<0.001) in the 30 mg prasugrel group. Late ade-
nosine diphosphate-induced platelet aggregation (LPA), by LTA was lower after
a 30 mg prasugrel RD compared with a 10 mg RD (mean LPA 8 +/–9 vs 14 +/–
12; p<0.001). Similar results were found using VerifyNow P2Y12 (mean PRU 38
+/–60 vs 87 +/–71; p < 0.001) and VASP assays (mean PRI 17 +/– 12 vs 33 +/–
15; p<0.001). No bleeding events were reported during the hospital stay. 
Conclusions: For patients receiving 300 mg clopidogrel therapy after an
ACS, a 30 mg RD of prasugrel compared to a 10 mg RD is associated with
further reduction in platelet function and markedly decreases the proportion of
P2Y12 inhibitors low responders.
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Background: Despite encouraging short and mid-term results with drug-
eluting stents (DES) in diabetic (DM) patients (pts) with coronary artery dis-
ease, the long-term efficacy is controversial. We assessed the influence of
long-term dual antiplatelet treatment (DAPLT) with aspirin and clopidogrel on
clinical outcome of DM pts treated with DES. 
Methods: The study included 610 consecutive DM pts (male 80%, mean
age 65±9 years) that had been treated with DES. Five years clinical follow-up
(FU) obtained in 584/610 (96%) of them. At the end of follow-up, 341 (58%)
pts were on DAPLT and 243 (42%) on single antiplatelet treatment (SAPLT).
The primary end-point was the combination of death (D), non-fatal myocardial
infarction (MI) and cerebrovascular accident (CVA), and was considered as
hard end-point (HEP). Stent thrombosis (ST) occurring -12 months after DES
implantation was considered as early (EST), and for >12 months, as late
(LST). The ARC definition for ST was used. 
Results: There was no difference in gender, age, risk factors profile,
unstable coronary artery disease, insulin treatment, extent of coronary artery
disease, and systolic left ventricular function between the two groups. At
12 months post PCI 546 (92%) pts were on DAPLT; the incidence of EST
(definite or probable) was 0.8%. The incidence of LST (definite or probable)
was 0.7%. There was no difference in the incidence of ST in pts treated with
DAPLT vs. SAPLT (1.4% vs. 1.6%, p: ns). At FU, HEP was observed in 18%
vs. 13%, in pts on DAPLT vs. SAPLT (p: ns). 
Conclusion: Long-term DAPLT in DM pts treated with DES implantation
is not associated with better clinical outcome or lower risk of definite or prob-
able ST. 
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Background: Stent thrombosis remains among the most feared complica-
tions of percutaneous coronary intervention (PCI) with stenting. However,
data on its incidence and predictors are sparse and conflicting. 
Objective: We aimed to perform a collaborative systematic review on inci-
dence and predictors of stent thrombosis. PubMed was systematically searched for
eligible studies from the drug-eluting stent (DES) era (1/2002-12/2010).
Methods: Studies were selected if including 2,000 patients undergoing
stenting or reporting on 25 thromboses. Study features, patient characteris-
tics, incidence and predictors of stent thrombosis were abstracted and pooled,
when appropriate, with random-effect methods (point estimate [95% confi-
dence intervals]).
Results: A total of 32 studies were identified (222,752 patients, 4,490 throm-
boses), with DES used in 89%. After a median of 22 months, definite, probable, or
possible stent thrombosis had occurred in 2.3% (2.0%; 2.6%), with acute in 0.3%
(0.2%; 0.5%), subacute in 1.1% (0.9%; 1.3%), late in 0.5% (0.4%; 0.6%), and very
late in 0.6% (0.4%; 0.7%). Similar figures were computed for studies reporting
only on DES, except for lower rates of acute ST (0.2% [0.1%; 0.2%]). From a total
of 47 candidate variables, the most reliable predictors of definite/probable stentPlatelet inhibition tested by Verify Now and VASP
